OPKO Health, Inc. · NASDAQ:OPK

OPKO Health — Technical Presentation (October 2014)

14 slides from OPKO Health's technical presentation, Oct 16, 2014

  1. Slide 1: The 4Kscore blood test for risk of aggressive prostate cancer

    The 4Kscore™ blood test for risk of aggressive prostate cancer

  2. Slide 2: When to use the 4Kscore Test?

    Prostate cancer tests When to use the 4Kscore™ Test ? Prognosis Prior to Monitoring in Gleason Prior to 1st negative (AS or Screening 6 for biopsy previous after aggressive biopsy therapy) disease* 4Kscore™ Test * If the 4Kscore Test was run prior to the biopsy

  3. Slide 3: Early detection of aggressive prostate cancer

    Early detection of aggressive prostate cancer Challenges • Serum PSA has a high false positive rate • Over 1 million prostate biopsies performed annually in US • 75% biopsies will have low-grade, indolent (Gleason 6) or no prostate cancer • Serious complications of biopsies include infection and hos

  4. Slide 4: The 4Kscore Test

    The 4Kscore™ Test • The only blood test that accurately identifies risk for aggressive prostate cancer • Aggressive prostate cancer is defined by both high-grade disease and long term clinical outcomes (rate of prostate cancer metastases) • Based on 10 years of work by scientists at Memorial Sloan-K

  5. Slide 5: The 4Kscore Test is based on 10 years of clinical research from ERSPC

    The 4Kscore™ Test is based on 10 years of clinical research from the European Randomized Study of Screening for Prostate Cancer (ERSPC) AUC Number Aggressive Prostate Key ERSPC Reference Cohort Population Subjects Cancer BMC Medicine 2008 6:19 Göteborg Unscreened 740 0.90 BMC Cancer 2010 10:635 Fran

  6. Slide 6: What is the 4Kscore Test?

    What is the 4Kscore™ Test? Components OPKO ALGORITHM Results 4 kallikrein levels % risk of having Total PSA aggressive prostate Free PSA cancer OPKO { Intact PSA hK2 for an individual patient + Age, DRE, and prior biopsy status

  7. Slide 7: Prospective, blinded, multicenter US study validates 4Kscore Test

    Prospective, blinded, multicenter US study validates 4Kscore™ Test • 1,012 patients enrolled in 26 centers for validation (Oct. 2013 to Apr. 2014) 26 Clinical study sites • Men scheduled for biopsy regardless of PSA, age, DRE status, prior biopsy • TRUS Biopsy of ≥ 10 cores • Excluded for treatments

  8. Slide 8: Gleason score distribution in Prospective US Study

    Gleason score distribution in Prospective US Study % All % All Gleason Grade N Cancers Patients Summary N = 470 N = 1,012 Negative 542 -- 53.6% Negative or Gleason 6 Negative or 77.2% prostate Gleasoncancer 6 6 239 50.9% 23.6% 7 (3+4) 108 23.0% 10.7% 7 (4+3) 59 12.6% 5.8% Aggressive 8 35 7.4% 3.5% 2

  9. Slide 9: The 4Kscore Test has the accuracy of a prostate biopsy for aggressive prostate cancer

    The 4Kscore™ Test has the accuracy of a prostate biopsy for aggressive prostate cancer 4Kscore™ Sensitivity AUC = 0.82 1 AUC = area under the curve PSA Larger AUC = better AUC = 0.69 1 accuracy for predicting aggressive prostate cancer AUC of other tests when applied AUC = 0.5 to aggressive disease

  10. Slide 10: The risk predicted by the 4Kscore Test is confirmed by prostate biopsy

    The risk of aggressive prostate cancer predicted by the 4Kscore™ Test is confirmed by prostate biopsy 239 aggressive Aggressive prostate cancer prostate cancers Actual detected by biopsy detected in 1,012 subjects Predicted

  11. Slide 11: 4Kscore Test is more accurate than total PSA alone

    4Kscore™ Test is more accurate than total PSA alone in predicting aggressive prostate cancer in subset of men with PSA 16-20ng/mL Total PSA DRE 4Kscore Test Result Biopsy Result 16.1 Normal 69% 7 16.4 Normal 1% Negative 16.4 Normal 8% Negative 16.6 Normal 50% 6 17.1 Normal 80% 9 17.3 Normal 89% 7 17

  12. Slide 12: The 4Kscore Test predicts the probability of distant metastases within 20 years

    The 4Kscore™ Test predicts the probability of distant metastases within 20 years 4Kscore™ Test 4Kscore Test Biomarkers Biomarkers > 7.5% > 7.5% (N = 922, 38%) 5 year = 2.4% 10 year = 5.6% 15 year = 9.9% 20 year = 16.4% 4Kscore Test Biomarkers ≤ 7.5% (N = 1510, 62%) 4Kscore™ Test 5 year = 0% 10 year

  13. Slide 13: Clear result reporting for informed decision making

    Based on your 4Kscore Test result, your probability for having a high-grade cancer is 5%. This means that if 100 men with your same 4Kscore Test result were to Clear result reporting for informed decision making Clinician Information Robert Blade, M.D. Patient Information Name: John Doe have a prost

  14. Slide 14: The 4Kscore Test Summary

    The 4Kscore™ Test Summary • Clinical utility was validated based on a decade of clinical research in over 30,000 men in Europe and the United States • Identifies the actual risk of aggressive prostate cancer for the individual patient • High grade prostate cancer pathology • Poor prostate cancer cli

OPKO Health — Technical Presentation (October 2014) on 6ix